This site is intended for Healthcare professionals only.

FDA raises concerns over Valeant’s eye drop


FDA raises concerns over Valeant’s eye drop

Valeant Pharmaceuticals International (VRX.TO) (VRX.N) said U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch + Lomb facility in Florida.

The U.S. Food and Drug Administration, in a complete response letter (CRL) regarding the eye drop for a type of glaucoma, raised concerns over Current Good Manufacturing Practice at the unit.

The letter did not identify any efficacy or safety issues with the eye drop, a latanoprostene bunod ophthalmic solution.

Valeant said it intends to meet the regulators and resolve these concerns, the company said in a statement.

Eye care unit Bausch + Lomb is one of Valeant’s core assets and a franchise to build on, billionaire investor and Valeant board member Bill Ackman said last week.



Source: Reuters
0 comment(s) on FDA raises concerns over Valeant’s eye drop

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted